These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2358803)

  • 1. MAO and L-dopa treatment of Parkinson's disease.
    Tyce GM; Dousa MK; Muenter MD
    J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
    Männistö PT; Tuomainen P; Toivonen M; Törnwall M; Kaakkola S
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):31-43. PubMed ID: 2113389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Karoum F; Chuang LW; Eisler T; Calne DB; Liebowitz MR; Quitkin FM; Klein DF; Wyatt RJ
    Neurology; 1982 May; 32(5):503-9. PubMed ID: 6803190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M
    Eur Neurol; 1981; 20(2):118-24. PubMed ID: 6260505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 15. Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Brissenden JA; Scerbak T; Albin RL; Lee TG
    Mov Disord; 2024 Jan; 39(1):76-84. PubMed ID: 38062630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
    Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC; Delini-Stula A; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
    Yu PH; Bailey BA; Durden DA; Boulton AA
    Biochem Pharmacol; 1986 Mar; 35(6):1027-36. PubMed ID: 3954792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of supplemental carbidopa on bioavailability of L-dopa.
    Cedarbaum JM; Kutt H; Dhar AK; Watkins S; McDowell FH
    Clin Neuropharmacol; 1986; 9(2):153-9. PubMed ID: 3085927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.